Pulmonary Adenocarcinomas of the Fetal Lung Type

Nakatani, Yukio; Kitamura, Hitoshi; Inayama, Yoshiaki; Kamijo, Seiko; Nagashima, Yoji; Shimoyama, Kiyoshi; Nakamura, Nobuo; Sano, Jinyu; Ogawa, Norio; Shibagaki, Tokuhiko; Resl, M; Mark, Eugene J.

doi:10.1097/00000478-199804000-00003

Cited by 123 publications

(45 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…as a type of pulmonary adenocarcinoma of the fetal lung 10. Those authors divided pulmonary adenocarcinomas of the fetal lung into low‐ and high‐grade forms, and low‐grade adenocarcinomas of fetal lung type (L‐FLACs) are also known as well‐differentiated fetal adenocarcinomas (WDFAs) in the WHO classification at present 10. Currently, both L‐FLACs/WDFAs and H‐FLACs are included as a subtype of adenocarcinoma in the WHO classification 11.…”

Section: Discussionmentioning

confidence: 99%

Blastomatoid pulmonary carcinosarcoma: A rare case report and review of the literature

et al. 2018

View full text Add to dashboard Cite

A 65‐year‐old never‐smoking woman presented to a local hospital, because an abnormal shadow was detected at the right lower lung field by annual chest X‐ray. Computed tomography (CT) revealed a 5‐cm tumor in segment 6 of her right lung and an enlarged subcarinal lymph node, suggesting metastasis. The lung tumor was diagnosed as adenocarcinoma by a CT‐guided percutaneous needle biopsy. She was referred to our hospital and underwent right lower lobectomy with lymph node dissection (ND2a‐2). A histopathological examination of the tumor showed a biphasic proliferation made of carcinomatous and sarcomatous components. The carcinomatous component consisted of glandular structures of atypical cells that possessed chromatin‐rich nuclear and clear cytoplasm, confirming high‐grade fetal adenocarcinoma. The sarcomatous component consisted of immature spindle cells that differentiated into chondrosarcoma. Immunohistochemically, the glandular structures expressed membranous beta‐catenin, and the ultimate diagnosis was blastomatoid variant of pulmonary carcinosarcoma. She received four courses of cisplatin plus vinorelbine as adjuvant chemotherapy and remained alive with neither recurrence nor distant metastasis at two and a half years after the operation. We experienced a rare case of blastomatoid pulmonary carcinoasarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Blastomatoid pulmonary carcinosarcoma: A rare case report and review of the literature

et al. 2018

View full text Add to dashboard Cite

show abstract

“…When mixtures occur with other histologic subtypes, the tumor should be classified according to the predominant component. 158 This tumor typically occurs in younger patients than other adenocarcinomas. Uniquely, these tumors appear driven by mutations in the beta-catenin gene, and the epithelial cells express aberrant nuclear and cytoplasmic staining with this antibody by immunohistochemistry.…”

Section: Pathologic Classificationmentioning

confidence: 99%

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Travis¹,

Brambilla²,

Noguchi³

et al. 2011

Journal of Thoracic Oncology

4,006

2,438

View full text Add to dashboard Cite

Introduction Adenocarcinoma is the most common histologic type of lung cancer. To address advances in oncology, molecular biology, pathology, radiology, and surgery of lung adenocarcinoma, an international multidisciplinary classification was sponsored by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society. This new adenocarcinoma classification is needed to provide uniform terminology and diagnostic criteria, especially for bronchioloalveolar carcinoma (BAC), the overall approach to small nonresection cancer specimens, and for multidisciplinary strategic management of tissue for molecular and immunohistochemical studies. Methods An international core panel of experts representing all three societies was formed with oncologists/pulmonologists, pathologists, radiologists, molecular biologists, and thoracic surgeons. A systematic review was performed under the guidance of the American Thoracic Society Documents Development and Implementation Committee. The search strategy identified 11,368 citations of which 312 articles met specified eligibility criteria and were retrieved for full text review. A series of meetings were held to discuss the development of the new classification, to develop the recommendations, and to write the current document. Recommendations for key questions were graded by strength and quality of the evidence according to the Grades of Recommendation, Assessment, Development, and Evaluation approach. Results The classification addresses both resection specimens, and small biopsies and cytology. The terms BAC and mixed subtype adenocarcinoma are no longer used. For resection specimens, new concepts are introduced such as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) for small solitary adenocarcinomas with either pure lepidic growth (AIS) or predominant lepidic growth with ≤5 mm invasion (MIA) to define patients who, if they undergo complete resection, will have 100% or near 100% disease-specific survival, respectively. AIS and MIA are usually nonmucinous but rarely may be mucinous. Invasive adenocarcinomas are classified by predominant pattern after using comprehensive histologic subtyping with lepidic (formerly most mixed subtype tumors with nonmucinous BAC), acinar, papillary, and solid patterns; micropapillary is added as a new histologic subtype. Variants include invasive mucinous adenocarcinoma (formerly mucinous BAC), colloid, fetal, and enteric adenocarcinoma. This classification provides guidance for small biopsies and cytology specimens, as approximately 70% of lung cancers are diagnosed in such samples. Non-small cell lung carcinomas (NSCLCs), in patients with advanced-stage disease, are to be classified into more specific types such as adenocarcinoma or squamous cell carcinoma, whenever possible for several reasons: (1) adenocarcinoma or NSCLC not otherwise specified should be tested for epidermal growth factor receptor (EGFR) mutations as the presence of these mutations is predictive o...

show abstract

“…It appears as a fetal lung at 10 to 15 weeks of gestation, resembling pulmonary blastoma, but the adjacent mesenchymal tissue is histologically benign (10). Recent WHO 2002 classification removed WDFA tumours from the pulmonary blastoma category and classified them as a variant of adenocarcinoma (11).…”

Section: Discussionmentioning

confidence: 99%